金鹰基金欧阳娟：创新药迎来业绩窗口期 脑机和AI医疗焕发产业新生

Core Insights - The innovative drug sector is entering a critical performance realization phase in 2026, driven by multiple catalysts and advancements in brain-computer interfaces and AI medical technologies [1][6][7] - Fund managers, including Ouyang Juan from Jinying Fund, express optimism about the innovative drug sector's upward trend, supported by domestic healthcare policies and China's competitive edge in global markets [1][6][7] - The potential of AI in healthcare is significantly underestimated, with expectations for new business models to emerge as AI applications in drug development, cancer screening, and personalized treatment evolve [2][7] Group 1: Industry Outlook - The innovative drug sector is expected to maintain a positive outlook, benefiting from ongoing support from domestic healthcare policies and the global competitiveness of Chinese innovative drugs [1][6] - The year 2026 is anticipated to be pivotal for the brain-computer interface industry, with significant changes expected in both domestic and international markets [3][8] - The AI healthcare sector is entering a phase of commercial exploration, with vast amounts of medical data and a growing demand for AI applications [2][8] Group 2: Investment Strategies - Focus areas for investment include innovative drugs with strong global competitiveness, which can benefit from both domestic and Western markets [3][8] - The innovative drug supply chain, including CXO and life sciences services, is projected to see a recovery in order growth as global financing accelerates [3][8] - The brain-computer interface and AI medical sectors are highlighted as emerging areas of interest, with potential for substantial growth and innovation [2][3][8]